Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial.
OBJECTIVE
--To ascertain if low-dose multiagent chemotherapy, with central nervous system prophylaxis and antiretroviral therapy, might be associated with increased efficacy and decreased risk of intercurrent infection in patients with malignant lymphoma related to the acquired immunodeficiency syndrome (AIDS).


METHODS
--A phase II prospective clinical trial, with median follow-up of 33 months.


METHODS
--Eight university hospitals, within the context of the AIDS Clinical Trials Units, sponsored by the National Institute of Allergy and Infectious Diseases.


METHODS
--Forty-two patients with AIDS-related malignant lymphoma. All were evaluable for toxicity assessment, and 35 for response.


METHODS
--A low-dose modification of the M-BACOD regimen (day 1): cyclophosphamide, 300 mg/m2 intravenously (IV); doxorubicin, 25 mg/m2 IV; vincristine sulfate, 1.4 mg/m2 IV; bleomycin, 4 mg/m2 IV; dexamethasone, 3 mg/m2 orally on days 1 through 5; methotrexate, 500 mg/m2 IV on day 15, with leucovorin rescue. Intrathecal cytosine arabinoside (50 mg) to all on days 1, 8, 21, and 28, with radiation therapy to a helmet field to those with central nervous system involvement. Zidovudine for 12 months after completion of four to six cycles of chemotherapy.


METHODS
--Response rate and number of opportunistic infections.


RESULTS
--Response rate was 51% with a complete response of 46%. Of 16 complete responses, relapse occurred in four, none isolated to the central nervous system. Opportunistic infections occurred in 21% of those receiving treatment. Median duration of survival among all 42 patients is 5.6 months, 6.5 months in 35 patients evaluable for response, and 15 months in patients with complete response. Lower concentration of CD4 cells, history of prior AIDS, bone marrow involvement, and stage IV disease were independently associated with decreased survival.


CONCLUSIONS
--Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance may be associated with durable remissions in AIDS-related lymphoma with fewer opportunistic infections than noted in prior reports.
Levine
A M
AM
University of Southern California School of Medicine, Los Angeles 90033.
Wernz
J C
JC
Kaplan
L
L
Rodman
N
N
Cohen
P
P
Metroka
C
C
Bennett
J M
JM
Rarick
M U
MU
Walsh
C
C
Kahn
J
J
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000401:mortality; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001761:Bleomycin / Q000008:administration & dosage; D002493:Central Nervous System Diseases / Q000188:drug therapy / Q000517:prevention & control*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006679:HIV Seropositivity / Q000188:drug therapy; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008223:Lymphoma / Q000188:drug therapy / Q000517:prevention & control*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000517:prevention & control; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009894:Opportunistic Infections / Q000150:complications; D011446:Prospective Studies; D014750:Vincristine / Q000008:administration & dosage; D015215:Zidovudine / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001761:Bleomycin; D015215:Zidovudine; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D002955:Leucovorin; D008727:Methotrexate